SG10201704166RA - Improving resistance to skeletal muscle fatigue - Google Patents
Improving resistance to skeletal muscle fatigueInfo
- Publication number
- SG10201704166RA SG10201704166RA SG10201704166RA SG10201704166RA SG10201704166RA SG 10201704166R A SG10201704166R A SG 10201704166RA SG 10201704166R A SG10201704166R A SG 10201704166RA SG 10201704166R A SG10201704166R A SG 10201704166RA SG 10201704166R A SG10201704166R A SG 10201704166RA
- Authority
- SG
- Singapore
- Prior art keywords
- skeletal muscle
- muscle fatigue
- improving resistance
- improving
- resistance
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623003P | 2012-04-11 | 2012-04-11 | |
| US201261646842P | 2012-05-14 | 2012-05-14 | |
| US201261693061P | 2012-08-24 | 2012-08-24 | |
| US201261735809P | 2012-12-11 | 2012-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201704166RA true SG10201704166RA (en) | 2017-06-29 |
Family
ID=49328282
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201704166RA SG10201704166RA (en) | 2012-04-11 | 2013-04-11 | Improving resistance to skeletal muscle fatigue |
| SG11201406359TA SG11201406359TA (en) | 2012-04-11 | 2013-04-11 | Improving resistance to skeletal muscle fatigue |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406359TA SG11201406359TA (en) | 2012-04-11 | 2013-04-11 | Improving resistance to skeletal muscle fatigue |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20150250784A1 (es) |
| EP (1) | EP2836590A4 (es) |
| JP (2) | JP6352244B2 (es) |
| KR (1) | KR102163931B1 (es) |
| CN (2) | CN111840294A (es) |
| AU (3) | AU2013245917A1 (es) |
| BR (1) | BR112014025251B1 (es) |
| CA (1) | CA2869675C (es) |
| EA (1) | EA032480B1 (es) |
| HK (1) | HK1206389A1 (es) |
| IL (2) | IL234886A (es) |
| MX (1) | MX2014012179A (es) |
| PH (1) | PH12014502286A1 (es) |
| SG (2) | SG10201704166RA (es) |
| WO (1) | WO2013155262A2 (es) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8299248B2 (en) | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| EA028060B1 (ru) | 2011-07-13 | 2017-10-31 | Сайтокинетикс, Инк. | Комбинированная терапия бокового амиотрофического склероза |
| AP2015008707A0 (en) | 2013-03-14 | 2015-09-30 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
| US20170042890A1 (en) * | 2014-04-29 | 2017-02-16 | Cytokinetics, Inc. | Methods of reducing decline in vital capacity |
| ES2901114T3 (es) | 2014-08-29 | 2022-03-21 | Tes Pharma S R L | Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa |
| CA2957804C (en) | 2014-09-09 | 2023-04-04 | Astellas Pharma Inc. | Pharmaceutical composition for prevention and/or treatment of urinary incontinence |
| KR20180120701A (ko) | 2016-02-12 | 2018-11-06 | 아스테라스 세이야쿠 가부시키가이샤 | 테트라히드로이소퀴놀린 유도체 |
| RU2019100559A (ru) | 2016-07-14 | 2020-07-14 | Пфайзер Инк. | Новые пиримидиновые карбоксамиды в качестве ингибиторов фермента ванин-1 |
| US10357493B2 (en) | 2017-03-10 | 2019-07-23 | Selenity Therapeutics (Bermuda), Ltd. | Metalloenzyme inhibitor compounds |
| IL302665A (en) | 2020-11-06 | 2023-07-01 | Cytokinetics Inc | Bicyclic 1,4-diazepenones and their therapeutic uses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005139081A (ja) * | 2003-11-04 | 2005-06-02 | Takada Seiyaku Kk | ビントペロール含有製剤 |
| US8227603B2 (en) * | 2006-08-01 | 2012-07-24 | Cytokinetics, Inc. | Modulating skeletal muscle |
| CN101522681B (zh) * | 2006-08-02 | 2012-10-03 | 赛特凯恩蒂克公司 | 特定的化学个体、组合物和方法 |
| US8299248B2 (en) * | 2006-08-02 | 2012-10-30 | Cytokinetics, Incorporated | Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use |
| CA2713864A1 (en) * | 2008-02-04 | 2009-08-13 | Cytokinetics, Incorporated | Certain chemical entities, compositions and methods |
| AR081331A1 (es) * | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| JP6345645B2 (ja) * | 2012-04-02 | 2018-06-20 | サイトキネティックス， インコーポレイテッド | 横隔膜機能を向上させるための方法 |
-
2013
- 2013-04-11 JP JP2015505896A patent/JP6352244B2/ja active Active
- 2013-04-11 EA EA201491666A patent/EA032480B1/ru not_active IP Right Cessation
- 2013-04-11 CN CN202010369880.5A patent/CN111840294A/zh active Pending
- 2013-04-11 US US14/391,087 patent/US20150250784A1/en not_active Abandoned
- 2013-04-11 BR BR112014025251-3A patent/BR112014025251B1/pt active IP Right Grant
- 2013-04-11 CN CN201380019567.7A patent/CN104395458A/zh active Pending
- 2013-04-11 WO PCT/US2013/036114 patent/WO2013155262A2/en active Application Filing
- 2013-04-11 KR KR1020147028128A patent/KR102163931B1/ko active IP Right Grant
- 2013-04-11 CA CA2869675A patent/CA2869675C/en active Active
- 2013-04-11 EP EP13775275.4A patent/EP2836590A4/en not_active Ceased
- 2013-04-11 SG SG10201704166RA patent/SG10201704166RA/en unknown
- 2013-04-11 SG SG11201406359TA patent/SG11201406359TA/en unknown
- 2013-04-11 AU AU2013245917A patent/AU2013245917A1/en not_active Abandoned
- 2013-04-11 MX MX2014012179A patent/MX2014012179A/es unknown
-
2014
- 2014-09-29 IL IL234886A patent/IL234886A/en active IP Right Grant
- 2014-10-10 PH PH12014502286A patent/PH12014502286A1/en unknown
-
2015
- 2015-07-22 HK HK15106995.5A patent/HK1206389A1/xx unknown
-
2017
- 2017-02-06 IL IL250473A patent/IL250473A0/en unknown
- 2017-12-28 JP JP2017253312A patent/JP6535727B2/ja active Active
-
2018
- 2018-02-08 AU AU2018200930A patent/AU2018200930A1/en not_active Abandoned
- 2018-11-30 US US16/206,747 patent/US20190167676A1/en not_active Abandoned
-
2019
- 2019-11-22 AU AU2019268177A patent/AU2019268177A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL234886A (en) | 2017-02-28 |
| AU2013245917A1 (en) | 2014-10-23 |
| US20150250784A1 (en) | 2015-09-10 |
| WO2013155262A3 (en) | 2013-12-27 |
| PH12014502286B1 (en) | 2014-12-15 |
| AU2018200930A1 (en) | 2018-03-01 |
| IL250473A0 (en) | 2017-03-30 |
| JP2015516392A (ja) | 2015-06-11 |
| AU2019268177A1 (en) | 2019-12-12 |
| JP2018048209A (ja) | 2018-03-29 |
| JP6352244B2 (ja) | 2018-07-04 |
| PH12014502286A1 (en) | 2014-12-15 |
| CA2869675A1 (en) | 2013-10-17 |
| EP2836590A4 (en) | 2016-04-13 |
| EA032480B1 (ru) | 2019-06-28 |
| EP2836590A2 (en) | 2015-02-18 |
| CN104395458A (zh) | 2015-03-04 |
| CN111840294A (zh) | 2020-10-30 |
| HK1206389A1 (en) | 2016-01-08 |
| WO2013155262A2 (en) | 2013-10-17 |
| US20190167676A1 (en) | 2019-06-06 |
| KR20160046694A (ko) | 2016-04-29 |
| CA2869675C (en) | 2022-06-14 |
| MX2014012179A (es) | 2015-07-14 |
| SG11201406359TA (en) | 2014-11-27 |
| BR112014025251B1 (pt) | 2021-03-02 |
| JP6535727B2 (ja) | 2019-06-26 |
| KR102163931B1 (ko) | 2020-10-12 |
| EA201491666A1 (ru) | 2015-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1206389A1 (en) | Methods for improving resistance to skeletal muscle fatigue | |
| EP2906114A4 (en) | PREDICTION OF THE RESPONSE TO A STIMULUS | |
| IL226745A0 (en) | Simulates a physical heart | |
| EP2842436A4 (en) | TRAINING CLOTHING WITH STEP | |
| HK1205031A1 (en) | Exercise mat | |
| EP2742938A4 (en) | AMINO-ACIDIC COMPOSITION FOR IMPROVED RECOVERY OF MUSCULAR TEMPERING | |
| SG11201501802VA (en) | Implement for training facial muscle | |
| ZA201504845B (en) | Trampolines | |
| HUE043603T2 (hu) | Sejtmentesített izommátrix | |
| GB201316224D0 (en) | Improvements in or relating to stairlifts | |
| GB201212069D0 (en) | Predicting resistance to disease | |
| EP2894215A4 (en) | FAT COMPOSITION | |
| PL2684481T3 (pl) | Sportowy lub fitnessowy kijek treningowy | |
| AP2015008378A0 (en) | Improvements relating to buoyancy-supported risers | |
| GB201215007D0 (en) | Improvements in or relating to luminaires | |
| GB201211746D0 (en) | Improvements in or relating to exercise devices | |
| GB2510810B (en) | Improvements in or relating to stairlifts | |
| GB2503199B (en) | Improvements in or relating to stairlifts | |
| GB2508793B (en) | Improvements in or relating to hardware | |
| GB2499408B (en) | Improvements in or relating to stairlifts | |
| GB2499828B (en) | Exercise bar | |
| ZA201406595B (en) | Sports grips | |
| GB201220690D0 (en) | Improvements relating to pasteurisation | |
| GB201221194D0 (en) | hand exerciser | |
| GB2499409B (en) | Improvements in or relating to stairlifts |